MiNK announces presentation of MiNK-215 data at AACR meeting

MiNK Therapeutics announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein targeting CAR-iNKT cell therapy, at the American Association for Cancer Research Meeting in San Diego, CA. “MiNK-215 represents a novel cellular therapeutic to overcome the limitations of immune checkpoint blockade therapy. The data presented at AACR demonstrate MiNK-215’s potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and CEO at MiNK. “Furthermore, these results accentuate MiNK-215’s versatility and synergistic potential when paired with immunotherapies such as Agenus’ botensilimab and balstilimab. This collaboration holds promise in bolstering the anti-tumor response, particularly in the formidable realm of microsatellite stable colorectal cancer.” Human organoid models of CRC with liver metastases revealed that MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms that include: Tumor stroma remodeling: MiNK-215 effectively remodels the tumor stroma, the supportive tissue surrounding the tumor to create a more favorable environment for immune cell infiltration and activity. Immune activation: By reprogramming the tumor microenvironment, MiNK-215 reduces the presence of immune-suppressive FAP expressing stellate cells and CXCL-12 expressing cells. Enhanced tumor killing: MiNK-215 recruits tumor-reactive T cells, pivotal in mounting an effective immune response against the tumor, ultimately leading to enhanced tumor eradication.